A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

NCT02066428 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Aeras

Collaborators